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ABSTRACT: Combined cooling and antisolvent crystallization enables crystallization of many pharmaceutical products, but its
process design typically neglects solvent composition influences on crystallization kinetics. This paper evaluates the influence of
solvent-dependent nucleation and growth kinetics on the design of optimal, multistage mixed-suspension, mixed-product
removal (MSMPR) crystallization cascades. The ability to independently select temperature and solvent compositions in each
stage of the cascade serves to greatly expand the attainable region for a two-stage cascade, with diminishing returns for
additional stages. Failure to include solvent-dependent kinetics can result in simulating incorrect attainable regions, active
pharmaceutical ingredient (API) yields, and crystal size distributions. This work also demonstrates that commonly employed
crystallization process design heuristics, such as equal antisolvent addition and decreasing temperature in successive stages, can
result in suboptimal process design if kinetics are strongly solvent dependent.
KEYWORDS: continuous crystallization, optimization, MSMPR, kinetics, antisolvent crystallization
■ INTRODUCTION
Antisolvent crystallization is frequently used to produce active
pharmaceutical ingredients (APIs) that exhibit high heat
sensitivity, weak solubility−temperature dependence, or poly-
morphism.1−4 Processes requiring antisolvent crystallization
may be enhanced further by employing combined cooling and
antisolvent crystallization (CCAC).5 Traditionally, most
antisolvent and CCAC pharmaceutical crystallizations are
batch processes. However, batch crystallization processes
have limitations. Batch processes are associated with longer
processing times, are cost- and labor-intensive, and have a
tendency to produce APIs with an inconsistent final product
quality.6,7 As a result, a shift is occurring toward using
continuous antisolvent crystallizers to decrease costs and
increase control.8−12 Mixed-suspension, mixed-product remov-
al (MSMPR) crystallizers represent one form of continuous
crystallizer that shows promise for continuous CCAC of APIs.
When designed well, MSMPRs are well-mixed vessels that
enable enhanced control of final product attributes, poly-
morphism, yield, and purity.13−15
Unfortunately, engineers and researchers currently lack a
systematic and generalized approach for the MSMPR cascade
design using kinetic parameters for antisolvent crystallization.
Although procedures exist for regressing solvent-dependent
kinetic (SDK) parameters from batch crystallization experi-
ments, these experiments have severe shortcomings. First,
batch crystallizations tend to undergo separate nucleation and
growth events; in an MSMPR crystallizer, growth and
nucleation occur simultaneously, competing to reduce super-
saturation.16 Second, batch experiments have limited use for
predicting secondary nucleation, which is the dominant
nucleation mechanism in an MSMPR crystallizer.17 Solvent-
dependent kinetic parameters must be regressed from
continuous crystallization experiments for a proper antisolvent
MSMPR crystallizer design. This is especially important for
multistage crystallization cascades, as having the ability to
operate at different temperatures and solvent compositions in
each stage expands the steady-state process design space. As
nucleation and growth rates vary as a function of the solvent
composition, tuning the solvent composition in each stage of
an MSMPR cascade allows a variety of final product attributes
to be achieved using a small number of MSMPR crystallizers.
Previous studies of continuous antisolvent crystallization
with MSMPRs focus on process design and optimization but
tend to neglect the solvent dependence of growth and
nucleation kinetics. Yang and Nagy optimized start-up
procedures for CCAC MSMPR cascades, demonstrating that
applying dynamic antisolvent and temperature profiles can
reduce start-up time and waste by almost 50%.18 Vetter et al.
introduced the concept of the attainable region for MSMPR
operation, which encompasses the set of operating conditions
where mean product particle size can be obtained, subject to
constraints on operating conditions.19 When applied to a
combined cooling and antisolvent crystallization (CCAC),
bounds on the solvent fraction and temperature in each
crystallizer restrict the size of the attainable region.19 Wong et
al. showed that incorporating recycle with the MSMPR
crystallizer can reduce the need for multiple MSMPR
crystallizers in a CCAC cascade.20 Most recently, Da Rosa
and Braatz presented openCrys, an open-source software for
CCAC modeling of crystallizers with turbulent flow, emphasiz-
ing that the optimal crystallizer design is nonobvious because
of the complex interplay between kinetics and transport
phenomena.21 The same complexity arises in the case of
CCAC in MSMPR crystallization, as well. However, the
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systems studied in each of these papers assumed that crystal
nucleation and growth kinetics were invariant with respect to
the solvent composition.
Studies of antisolvent crystallization indicate that beyond its
impact on thermodynamics, solvent composition can have a
substantial effect on crystallization kinetics. Regarding
nucleation, Zhang et al. demonstrated that solution composi-
tion strongly influenced nucleation kinetics in the continuous
antisolvent crystallization of a proprietary compound, affecting
the optimal location of the antisolvent addition in the
crystallization cascade.22 Regarding growth, Garg et al.
proposed a mechanistic modeling that incorporates both
size-dependent and solvent-dependent growth kinetics to
predict the mean particle size in a batch antisolvent
crystallizer.23 Recently, we demonstrated that growth and
nucleation kinetics parameters can be profoundly influenced by
solvent composition, as even small changes in solvent
composition can drastically increase crystal growth and
nucleation rates in a continuous MSMPR crystallizer.24 To
accurately predict performance in a single MSMPR crystallizer,
the temperature and solvent dependence of the kinetics should
be studied and incorporated in crystallization process design
models.
To speed the CCAC MSMPR cascade design, it may seem
intuitive to place additional constraints on the process
optimization. This could include requiring equal mass
deposition or production rates in each stage or requiring
equal antisolvent addition (EAS) in each stage. Most
commonly, a constraint is imposed to require the temperature
to remain the same or decrease in each successive stage when
designing continuous cooling or CCAC crystallization
processes.18,19,25,26
In this work, the solvent-dependent and temperature-
dependent kinetics for a proprietary API have been used to
optimize a steady-state, N-stage MSMPR cascade. For this
study, maximizing yield is the primary process objective for the
model. The simulated crystallization process uses combined
cooling and antisolvent crystallization and is subject to
manufacturer-imposed process constraints. After determining
the best set of operating conditions for each MSMPR
crystallizer cascade, the attainable region for each cascade is
simulated. These results are then compared to optimization
results when solvent-dependent kinetics are neglected. Finally,
for the case of the two-stage MSMPR cascade, the
optimization results are compared to optimization results
obtained if common MSMPR design heuristics are used. Two
heuristics are evaluated: (1) where equal antisolvent addition
volumes are added to each crystallizer and (2) where the
temperature is required to remain the same or decrease in each
stage. Ultimately, it is shown that the design of a CCAC
MSMPR cascade process is nonobvious when solvent-depend-
ent nucleation and growth kinetics are considered.
■ MATHEMATICAL MODELING
System Description. The API of interest for this study is a
proprietary compound that was supplied by Novartis Interna-
tional AG. Throughout this work, this compound will be
referred to as API. API is crystallized using a three-solvent
system, where water is the antisolvent and a 92 vol % ethanol
(EtOH)/ 8 vol % tetrahydrofuran (THF) solution is used as
the solvent. Currently, API is manufactured using a batch
crystallization process where the antisolvent is added to induce
crystallization, then cooling occurs to increase the extent of
crystallization. This batch process takes more than 12 h, so
there is a great opportunity to reduce the processing time by
developing a continuous process for this compound.
API exhibits solvent-dependent thermodynamics and
kinetics, which were studied previously.24 The solubility of
API is a strong function of both temperature and solvent
composition, as shown in Figure 1. Based on the previous
findings, API solubility in stage i, ci*, is estimated using a
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where Ti represents the crystallizer temperature in stage i, νs,i is
the solvent volume fraction in the crystallizer at stage i, and
values for each solubility parameter, ζkl, are presented in Table
1. The solvent volume fractions are defined on an API-free
basis as: (volume of THF + volume of EtOH)/(volume of
THF + volume of EtOH + volume of water).








where the saturation concentration in each stage is calculated
using the solubility expression provided in eq 1. By employing
this supersaturation expression, the same kinetic prefactors and
growth factors may be used from previous research on the API
of interest.24
Figure 1. Solubility of API as a function of the solvent fraction and
temperature.
Table 1. Solubility Parameter (ζkl) Values
a
k ↓/l → 1 2 3 4
1 −8070.4 12 537.09 −4972.05 −16 622.6
2 339 770.2 −531 620 212 470.6 708 640.1
3 1219.833 −1892.13 749.4551 2507.269
aThe calculated solubilities have units of g API/kg solution.
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API kinetics are assumed to follow a power law form for
growth





where Gi, kg,i, and gi are the growth rate, lumped growth















where Bi is the nucleation rate in the ith stage, kb,i is the
nucleation prefactor in the ith crystallizer, is the nucleation
power in the ith stage, τi is the residence time in stage i, and
μ3
(i) is the third moment of the crystal population in stage i.
This expression for API nucleation assumes that secondary
nucleation is the predominant nucleation mechanism in each
MSMPR crystallizer. Previous research also indicates that API
crystal growth kinetics exhibit substantial solvent dependence
and temperature dependence.24 This functionality is estimated












= −k v3104 exp( 0.86 )i ig1, s, (6)
= −k v0.0207 exp( 8.395 )g i i0, s, (7)
=g 1i (8)
For these expressions, kg0,i and kg1,i are the growth prefactor
and growth activation prefactor in stage i, respectively.
Similarly, previous research indicates that API crystal
nucleation kinetics exhibit strong solvent dependence but
minor temperature dependence.24 For this reason, temper-
ature-dependent nucleation kinetics are neglected, and the
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By incorporating the solvent and temperature dependence of
the kinetic prefactors, crystallizer cascade performance can be
more accurately predicted.
Multistage MSMPR Model. Continuous steady-state N-
stage MSMPR cascade systems were simulated in MATLAB
using population balance equations, where N = 1, 2, or 3
stages. In using this population balance modeling scheme, the
following assumptions are made:
1. The feed solution contains no crystals.
2. The mixing of solvent and antisolvent does not affect the
total solution volume, and the crystalline phase has a
negligible contribution to the total suspension volume.
3. All crystals nucleate from a size of 0 μm.
4. There is no growth dispersion or size-dependent growth,
and the crystal shape factor is independent of kinetics
and solvent composition.
5. Crystals experience negligible agglomeration and break-
age in the crystallizer.
6. Each crystallizer is well-mixed, so the outlet of the
crystallizer has the same composition as the crystallizer
contents.
7. All crystallization occurs within the cascade crystallizers.
8. All crystallizers operate at steady state.
There are four main parts of the steady-state crystallization
model: an API material balance, a population balance, and two
kinetic expressions, one for crystal nucleation and one for
crystal growth. In this work, we chose to optimize the
crystallization cascades based on the steady-state moments of
the crystal population. Based on the previous assumptions and
because clear feed enters the first crystallizer, the zeroth
moment of the first crystallizer is
τ

























in each additional crystallizer, where
∫μ =
∞





represents the jth moment at stage i, L is the characteristic
crystal length, and ni is the population density at stage i.
6
Similarly, the first- and higher-order moments are
τ



















































is the volume-based dilution factor, where
ρ α ρ α ρ= + −− (1 )i i i isoln, soln, 1 AS (18)
describes the density of the solvent mixture in stage i. In these
expressions, ρAS represents the density of the antisolvent.
The simplified material balance governing the API in the
crystallizer is described by18
α τ τ













where ci is the API concentration in the ith stage. For this
system, the shape factor, kν, and crystal density, ρc, are assumed
to be constants with values of 0.21 and 1.228 kg/m3,
respectively. Finally, the kinetic expressions for API nucleation
and growth are the same expressions provided in eqs 3 and 4,
where the kinetic prefactors and powers are those described in
eqs 5−10. A consolidated statement of this MSMPR model is
provided in the Supporting Information.
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Process Constraints. For the studied system, there are a
number of specifications, which are placed on the final
crystallized product by the manufacturer. The following
specifications must be met during the crystallization process:
1. The yield must equal or exceed 90% exiting the final
crystallizer: Y ≥ 0.90.
2. The d50 of the crystal size distribution (CSD) must equal
or exceed 40 μm exiting the final crystallizer: d50 ≤ 40
μm.
3. The d90 of the CSD must not exceed 240 μm exiting the
final crystallizer: d90 ≤ 240 μm.
These specifications provide the minimum set of constraints
on the final product quality, which are specified by the
manufacturer. Though more rigorous constraints on CSD or
mean crystal size could be imposed, those constraints are
outside of the scope of the optimization presented in this
report. The primary goal of the current optimization is to
maximize API yield.
Aside from these specifications on the final crystallized
product, the process operating conditions have also been
constrained:
1. API feed enters the first crystallizer at a temperature of
55 °C and a concentration of 70 g/kg solution (on an
antisolvent-free basis): c0 = 70 g/kg.
2. The solvent fraction of the feed stream is 100% solvent
(on an API-free basis): α0 = 1.
3. The solvent fraction must not exceed 90 vol % and must
not be reduced below 44 vol % in any crystallizer: 0.44 ≤
υs,i ≤ 0.90.
4. The solvent fraction must remain the same or decrease
in each stage: νs,i < νs,i−1.
5. Each crystallizer temperature cannot exceed 30 °C and
may not be colder than 10 °C: 10 °C ≤ Ti ≤ 30 °C.
6. The total residence time of the crystallization cascade
cannot exceed 3 h: τ τ∑ = ≤= 180 min.i
N
i1 tot
A consolidated statement of the MSMPR model along with
these process constraints is provided in the Supporting
Information.
MSMPR Cascade Simulations. To estimate the optimal
API processing conditions for the one, two, or three-stage
MSMPR cascades, thousands of sets of reactor operating




T , ,i i i (20)











Temperature, solvent composition, and residence time are
selected for each crystallization stage to comprise the set of
operating conditions. Based on the number of stages in the
cascade, the step size for each of these process variables was
varied to restrict the number of crystallizers that were
simulated. The variation in operating conditions used for
each cascade simulation is provided in Table 2. For each set of
operating conditions, each crystallizer was modeled using the
MSMPR steady-state cascade model subject to the process
constraints, which are outlined in the Process Constraints
section. Based on the yield and mean volume particle size
(L4,3) for each simulated crystallization cascade, the attainable
region associated with the parameter space was mapped. For
this work, the volume-averaged mean size is calculated



















where L4,3 is the volume-averaged mean size, n is the crystal
number density, and L is the size of the characteristic crystal
dimension.
To compare crystallizer performance to the performance of
crystallizer cascades with additional constraints that are
commonly assumed for cooling and/or antisolvent crystal-
lizations, the crystallizer simulations were replicated with one
additional type of constraint or heuristic imposed. First, the
optimization was again completed using solvent-independent
kinetics (SIK) for the cases of the one-, two-, and three-stage
cascades. For the case of solvent-independent kinetics, kb and
kg were calculated as constants, assuming that kinetics were
measured at a solvent composition of νs = 0.48. At solvent
fractions below νs = 0.48, the solubility curve is fairly flat.
Therefore, νs = 0.48 is the most likely choice of solvent
composition if the operating solvent composition was chosen
based on the solubility data alone. Next, the MSMPR cascade
optimization was repeated using solvent-dependent kinetics for
the two- and three-stage cascades, where equal antisolvent
addition was required in each stage. Finally, the simulation was
repeated for the two-stage MSMPR cascade where the
temperature was required to stay constant or decrease in the
second stage. The mathematical statements associated with
each of these additionally imposed process constraints are
provided in the Supporting Information.
Table 2. Conditions for One-, Two-, and Three-Stage Steady-State MSMPR Cascade Simulations
stage Tmin (°C) Tstep (°C) Tmax (°C) νs,min νs,step νs,max τmin (min) τstep (min) τmax (min)
Single-Stage (273 060 Simulations)
1 10 0.5 30 0.44 0.0025 0.90 5 5 180
Two-Stage (874 800 Simulations)
1 10 2.5 30 0.44 0.02 0.90 20 20 160
2 10 2.5 30 0.44 0.01 0.90 20 20 160
Three-Stage (490 500 Simulations)
1 10 10 30 0.44 0.046 0.90 20 40 140
2 10 10 30 0.44 0.046 0.90 20 40 140
3 10 5 30 0.44 0.02 0.90 20 40 140
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■ RESULTS AND DISCUSSION
Cascade Optimization Results. Results of the simu-
lations for optimal operating conditions in the one-, two-, and
three-stage crystallization cascades are provided in Table 3.
When solvent-dependent kinetics are considered, the optimal
operation occurs at the lowest temperature and the lowest
solvent fraction for each crystallizer in the cascade, regardless
of the number of stages. This means that the antisolvent
addition occurs only on the first stage. The selection of the
lowest solvent fraction results from two cooperating phenom-
ena: (1) from a thermodynamic perspective, an increase in
supersaturation results from minimizing solubility at low
solvent fractions and (2) from a kinetic perspective, there is
an exponential increase in prefactors kb and kg at low solvent
fractions.
Both of these phenomena work to increase the growth and
nucleation rates, leading to increased yield. The selection of
the lowest temperature for each stage occurs because the
resulting increase in the growth and nucleation rates from
lowering the API solubility (and, thereby, increasing super-
saturation) is not offset by the retardation in kinetics from
reduced temperatures. Residence time appears to be split
approximately equally among the crystallizers in the multistage
cascades but is limited for the single-stage case.
Repeating the cascade simulation in the vicinity of the low
solvent fraction and low temperature indicates that residence
time is optimally split almost equally between each of the
crystallizers in the cascades, with earlier stages requiring
slightly more residence time for maximum yield. These results
are provided in Table 4, where the optimal residence time in
each stage was determined within ±1 min.
As the number of stages in the MSMPR cascade increases,
the yield increases. However, the mean particle size associated
with the highest yield decreases with an increasing number of
cascade stages. Though the results indicate that the highest
yield can be obtained in a three-stage crystallizer, there is only
a little increase in yield when transitioning from a two-stage
MSMPR cascade to a three-stage MSMPR cascade at optimal
operating conditions. Furthermore, it is possible to meet all
particle size and yield specifications in a single crystallizer.
Therefore, the use of multiple MSMPR crystallizers in a
cascade is not necessarily required for this process. Figure 2
confirms these findings. Figure 2a shows that as the number of
stages increases, the volumetric particle size distribution shifts
slightly to the left toward lower mean particle sizes. However,
the attainable region greatly expands once multiple MSMPR
crystallizers are used in a cascade, as shown in Figure 2b.
Having the ability to operate at different temperatures and
solvent compositions in each stage of the MSMPR cascade
expands the steady-state process design space. As nucleation
and growth rates vary as functions of the solvent composition,
tuning the solvent composition in each stage of an MSMPR
cascade allows a variety of final product attributes to be
achieved using a small number of MSMPR crystallizers in the
cascade. For example, the attainable region expands greatly
Table 3. Optimization Results for the Steady-State MSMPR Cascades
number of cascade stages/simulation type T1 (°C) T2 (°C) T3 (°C) νs,1 νs,2 νs,3 τ1 (min) τ2 (min) τ3 (min) Y (wt %) L4,3 (μm)
Single-Stage
solvent-dependent kinetics 10 0.44 160 97.08 142.9
solvent-independent kinetics 10 0.44 70 90.52 143.0
Two-Stage
solvent-dependent kinetics 10 10 0.44 0.44 100 80 99.47 127.0
solvent-independent kinetics 10 10 0.44 0.44 60 120 99.43 137.6
equal volumes of antisolvent addition 10 10 0.61 0.44 80 100 98.66 129.3
Three-Stage
solvent-dependent kinetics 10 10 10 0.44 0.44 0.44 60 60 60 99.49 111.8
solvent-independent kinetics 10 10 10 0.44 0.44 0.44 60 60 60 99.49 137.6
equal volumes of antisolvent addition 10 10 10 0.70 0.54 0.44 20 60 100 98.99 129.8
Table 4. Steady-State MSMPR Cascade Simulation Results with Refined Residence Time
number of cascade stages T1 (°C) T2 (°C) T3 (°C) νs,1 νs,2 νs,3 τ1 (min) τ2 (min) τ3 (min) Y (wt %) L4,3 (μm)
1 10 0.44 163 97.11 143.5
2 10 10 0.44 0.44 93 87 99.47 124.7
3 10 10 10 0.44 0.44 0.44 63 60 57 99.49 113.2
Figure 2. Volume-based CSD (a) at optimal MSMPR operating
conditions and attainable region (b) for the one-, two-, and three-
stage MSMPR cascade.
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when shifting from using one MSMPR to using two MSMPRs
in the cascade. In particular, lower mean particle sizes are
achievable in the two-stage MSMPR cascade, when compared
with a single MSMPR crystallizer. Maximum yield is increased
for the multistage MSMPR cascade, as well. The area of the
attainable region expands again when transitioning from the
two-stage to the three-stage crystallization process, though
there are diminishing returns for adding a third crystallizer to
the cascade. If at least two stages are used in the MSMPR
cascade, then a high yield and mean size can be selected
independently by choosing the proper set of operating
conditions (temperature, solvent fraction, and residence
time). For these reasons, it may be preferable to use two
stages instead of a single-stage MSMPR cascade. It is unlikely
that more than two MSMPRs would be required for this
process.
Influence of Solvent-Dependent Kinetics on Single-
Stage MSMPR Simulations. The first evaluation was on the
influence of including solvent-dependent kinetics on the
calculated attainable region and the volumetric size distribu-
tion of the particles exiting the crystallizer in a single-stage
MSMPR. Figure 3a indicates that the attainable region that
incorporates solvent-dependent kinetics is much larger than
would be predicted if it was erroneously assumed that the
kinetics were solvent-independent. The attainable region area
is expanded because the growth and nucleation rates are much
larger at lower solvent fractions with the solvent-dependent
kinetics. If the volumetric particle size distributions are
considered, they do not change with incorporating solvent-
dependent versus solvent-independent kinetics (Figure 3b).
This is expected, as the broadness of a CSD in an ideal, single-
stage MSMPR is determined by the residence time
distribution, which is the same in both cases. However, note
that this distribution is normalized, and the number of particles
in each size range is greatly increased when solvent-dependent
kinetics are incorporated. In fact, the yield is predicted to be
almost 6.6% higher if solvent-dependent kinetics are
incorporated in the MSMPR model (Table 3).
Including solvent-dependent kinetics also reduces the
expected mean particle size slightly in the single-stage case.
This trend is also seen in the two- and three-stage cases and
will be discussed further.
Influence of Solvent-Dependent Kinetics on Two-
Stage MSMPR Simulations. Figure 4a shows the effect of
neglecting solvent-dependent kinetics when simulating the
attainable region for the two-stage MSMPR cascade. If the
dependence on the solvent is neglected, then the attainable
region appears to be less than half the size than would
otherwise be simulated. Though similar maximum yields are
predicted, lower mean sizes are not seen as being achievable if
the solvent-dependent kinetics are excluded. Similarly, the
CSD associated with the maximum yield shifts left when the
solvent-dependent kinetics are included (Figure 4b). Lower
mean sizes are obtained because the nucleation rates at the
optimal solvent fraction are higher in the case of solvent-
dependent versus solvent-independent kinetics, leading to
greater mass deposition for crystal nucleation.
Influence of Solvent-Dependent Kinetics on Three-
Stage MSMPR Simulations. Though maximum yield
achievable in the three-stage cascade is only marginally better
than in the two-stage cascade, it is worth considering what
happens if solvent-independent rather than solvent-dependent
kinetics are used to model the three-stage MSMPR cascade.
Figure 3. Attainable region (a) and volume-based CSD at optimal
MSMPR operating conditions (b) for cases of solvent-dependent
kinetics (SDK) and solvent-independent kinetics (SIK) in a single
MSMPR.
Figure 4. Attainable region (a) and volume-based CSD at optimal
MSMPR operating conditions (b) for cases of solvent-dependent
kinetics (SDK) and solvent-independent kinetics (SIK) in a two-stage
MSMPR cascade. The volume-based CSD at optimal MSMPR
operating conditions is also displayed for the case of equal antisolvent
addition (EAS).
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Similar to the two-stage cascade, Figure 5a indicates that
neglecting the solvent-dependent kinetics drastically reduces
the area of the attainable region. Figure 5b shows the
differences in the volumetric CSD for the cases where
solvent-dependent kinetics are incorporated or neglected for
the three-stage MSMPR cascade and confirms the findings that
are shown in Table 3. Again, the mean size is overpredicted
and the yield is underpredicted at the optimal set of operating
conditions.
Regardless of the number of stages simulated in the MSMPR
cascade, incorporating solvent-dependent kinetics is of extreme
importance. Neglecting the dependence of the kinetics on the
solvent composition leads to substantial differences in
calculating API yield, mean size, CSD, and the attainable
region in each cascade.
Shortcomings of Common Antisolvent Crystalliza-
tion Heuristics. Beyond using solvent-independent instead of
solvent-dependent kinetics, there are a number of common
heuristics that are used in simulating crystallization cascades
with antisolvent crystallization or CCAC. It was decided to
compare the attainable regions, which one would obtain using
these common heuristics, to the attainable regions obtained if
no additional constraints beyond the yield and CSD
constraints were imposed on the crystallizer cascade perform-
ance.
For example, a common heuristic for designing antisolvent
crystallization processes is to require equal antisolvent addition
in each stage. If the constraint of equal antisolvent addition is
imposed, the attainable region shrinks drastically, and the
maximum yield achievable in the process is reduced.
Furthermore, the smaller mean sizes are not achievable. This
is shown in Figure 6. Although direct restrictions or constraints
on the mean size were not imposed, it may preferable based on
downstream processing requirements to aim for a smaller
mean size, especially for high-potency APIs. Therefore,
requiring equal antisolvent addition is unnecessary and restricts
the attainable final product mean size exiting the final
crystallizer.
Another common approach for determining the attainable
region for antisolvent crystallizers and selecting operating
conditions includes implementing a constraint that requires the
temperature in each stage to be less than or equal to the
temperature in the preceding stage. This is the most common
constraint used in cooling and CCAC crystallizations. In
Figure 7, it is shown how this restriction affects the attainable
region. The area of the attainable region is approximately
unchanged because the boundaries of the attainable region are
not formed at operating conditions where the temperatures in
successive stages are higher than the preceding stages. For
example, at the top yields achievable, the temperatures are
equal in each stage. Though implementing this constraint of
decreasing the temperature in each additional stage would have
reduced the computational time to solve the optimization
problem, this constraint is unnecessary and may lead to false
conclusions based on the other constraints selected for
operating conditions.
Figure 5. Attainable region (a) and volume-based CSD at optimal
MSMPR operating conditions (b) for cases of solvent-dependent
kinetics (SDK) and solvent-independent kinetics (SIK) in a three-
stage MSMPR cascade. The volume-based CSD at optimal MSMPR
operating conditions is also displayed for the case of equal antisolvent
addition (EAS).
Figure 6. Comparison of attainable region area for the mean size and
yield if equal antisolvent volume addition (EAS) in each stage is
imposed as a process constraint for the two-stage MSMPR cascade.
Figure 7. Comparison of the attainable region area for the mean size
and yield if a decreasing temperature constraint is imposed in the two-
stage MSMPR cascade.
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At high total residence times in the two-stage MSMPR
cascade, there is a plateau in the maximum yield achievable
(Figure 8). If the total residence time in the system was
restricted to be substantially smaller than 180 min, the
attainable region would change such that it may be beneficial
to increase the temperature in successive stages. For this
particular system, an example of such a case occurs when an
objective is to maximize the production rate instead of simply
maximizing the yield in the final crystallization stage.
As it can be seen from Figure 8, reducing the total residence
time to approximately 35 min can lead to significant gains in
the production rate (defined in kg/min of the generated solid
API, relative to the crystallizer size) against the conditions of
maximum yield at 180 min residence time.
At low residence times, the optimal residence time is split
unevenly between the two stages and favors increasing the
temperature from 25 °C in the first stage to 30 °C in the
second stage to compensate for the limited residence time
(Table 5). This is due to the tradeoff that occurs in the growth
and nucleation rates due to changes in temperature. Temper-
ature affects growth and nucleation rates in two ways. As the
temperature is increased, growth and nucleation rates increase
due to the increase in the kinetic prefactors, kb and kg.
However, temperature increases also increase the solubility in
the system, leading to a kinetic inhibition from lower operating
supersaturations as well as lower solids concentration at the
same residence time. In the limit of low residence times in the
multistage crystallizer cascade, the reduction in supersaturation
from the increased temperature is more than offset by the
increase in growth and nucleation rates from increasing the
kinetic prefactors. Therefore, if a process objective is to
maximize the production rate instead of yield, it is beneficial to
remove the limitation that the temperature must remain the
same or decrease in each successive stage.
Ultimately, neither of the two commonly used crystallizer
cascade design heuristics for antisolvent crystallization should
be used for systems where the growth and nucleation kinetics
are solvent-dependent.
■ CONCLUSIONS
In this work, a series of steady-state MSMPR cascades was
simulated to evaluate the effect of incorporating solvent-
dependent kinetics in antisolvent crystallization process design.
Antisolvent crystallization cascade design should account for
effects of the solvent composition on crystallization kinetics.
Failure to include solvent-dependent kinetics could result in
the simulation of incorrect attainable regions, API yields,
crystal morphologies, and CSDs. In multistage crystallization
cascades, the selection of the solvent composition may have a
stronger influence on the attainable product attributes than
other process operating conditions such as temperature or
residence time.
Beyond demonstrating the need to include solvent-depend-
ent kinetics in antisolvent crystallizer designs, it was also
demonstrated that some of the commonly employed
crystallization process design heuristics should not be used
for processes that have strongly solvent-dependent kinetics.
For processes where it is beneficial to constrain the mean
particle size, requiring equal antisolvent addition can prevent
the lowest mean particle sizes from being obtained at high
yields. It was also demonstrated that constraining the
temperature in the crystallizer to remain the same or decrease
in each successive MSMPR in the cascade is another
unnecessary process constraint. For processes where a
maximum production rate at high yield is preferred to
maximum yield, it may be beneficial to operate the crystallizer
cascade by increasing the temperature in later stages, especially
in the limit of short residence times.
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.oprd.9b00244.
Consolidated statement for the mathematical models;
additional process constraints for the evaluation of
optimization heuristics (PDF)
(PDF)
Figure 8. Yield and relative production rate as a function of the total
residence time allowed in the two-stage MSMPR cascade. Maximum
production occurs at a total residence time of approximately 35 min.
Table 5. Optimal Operating Conditions for a Two-Stage MSMPR Cascade with Selected τ1, τ2
T1 (°C) T2 (°C) νs,1 νs,2 τ1 (min) τ2 (min) τtot (min) Y (wt %) relative production rate L4,3 (μm)
10 10 0.44 0.44 80 80 160 99.47 1.12 120.1
10 10 0.44 0.44 65 55 120 99.44 1.50 114.0
10 10 0.44 0.44 50 30 80 99.36 2.25 106.8
10 10 0.44 0.44 40 20 60 99.18 2.99 101.0
10 10 0.44 0.44 35 20 55 99.08 3.26 97.7
10 10 0.44 0.44 35 15 50 98.90 3.58 97.7
10 10 0.44 0.44 30 15 45 98.59 3.96 93.9
15 17.5 0.44 0.44 25 15 40 97.89 4.43 95.7
25 30 0.44 0.44 20 15 35 96.08 4.97 102.5
30 30 0.44 0.44 15 15 30 81.76 4.93 101.3
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■ NOMENCLATURE
Bi, nucleation rate at the ith stage, kg/min
bi, nucleation power in ith crystallizer
ci, API concentration in the liquid phase of the ith stage
crystallizer, kg/kg solution
ci*, saturation concentration in ith crystallizer, kg/kg
solution
c0, inlet API concentration, kg/kg solution
Gi, growth rate at the ith stage, μm/min
gi, growth power in ith crystallizer
i, stage number
j, moment number
kb,i, nucleation prefactor in ith crystallizer, μm
2/min
kg,i, lumped growth prefactor in ith crystallizer, μm/min
kg0,i, growth prefactor in ith crystallizer, μm/min
kb1,i, growth activation prefactor in ith crystallizer, K
kv, volume shape factor
L, characteristic crystal length, μm
L4,3, volume-based mean crystal size, μm
ni, number density at stage i, μm/kg
Ti, temperature in ith crystallizer, K
vs,i, solvent volume fraction (mL solvent/mL solvent +
antisolvent) in stage i
Y, yield, %
αi, volume-based dilution factor at the ith stage
αmf,i, mass-based dilution factor at the ith stage
μj
(i), jth moment in the ith stage, μmj/kg
ζkl, solubility parameter
ρAS, antisolvent density, kg/m
3
ρc, crystal density, kg/μm
3
ρsoln, solution density, kg/m
3
σi, supersaturation in ith crystallizer
τi, residence time at the ith stage, min
τtot, total residence time for crystallization process, min
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